Study S001861

A Randomized, Open-label, Placebo-controlled, Repeat-dose Study to Assess the Pharmacokinetics and Pharmacodynamics of 5 Micrograms Exenatide Administered Subcutaneously Twice Daily for 7 Days in Healthy Normal Volunteers and in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT00259896
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 30
Start: 2005-10
Lead sponsor: GlaxoSmithKline
Conditions: Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2
Interventions: DRUG:exenatide
Results posted: FALSE

Registered primary outcomes

Pharmacodynamic measurements during 7 days of dosing. []

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.